ORTHOCLONE OKT3

First-line therapy or last option?

Douglas Norman, C. F. Shield

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

ORTHOCLONE OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ) a monoclonal anti-T cell antibody with in vitro immunosuppressive properties, is more effective than high-dose steroids for reversing acute renal allograft rejection. It has been used as first-line therapy for first rejection and as the last option for acute rejection, when other therapies have failed. The following report details the experience of two transplant centers on use of ORTHOCLONE OKT3 in renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)949-953
Number of pages5
JournalTransplantation Proceedings
Volume18
Issue number4
StatePublished - 1986

Fingerprint

Muromonab-CD3
Kidney
Immunosuppressive Agents
Allografts
Steroids
T-Lymphocytes
Transplants
Antibodies
Therapeutics
Pharmaceutical Preparations
Transplant Recipients
Thomsen-Friedenreich antibodies
In Vitro Techniques

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

ORTHOCLONE OKT3 : First-line therapy or last option? / Norman, Douglas; Shield, C. F.

In: Transplantation Proceedings, Vol. 18, No. 4, 1986, p. 949-953.

Research output: Contribution to journalArticle

@article{44d9f993eec846cdbc820e56a5d9937b,
title = "ORTHOCLONE OKT3: First-line therapy or last option?",
abstract = "ORTHOCLONE OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ) a monoclonal anti-T cell antibody with in vitro immunosuppressive properties, is more effective than high-dose steroids for reversing acute renal allograft rejection. It has been used as first-line therapy for first rejection and as the last option for acute rejection, when other therapies have failed. The following report details the experience of two transplant centers on use of ORTHOCLONE OKT3 in renal transplant recipients.",
author = "Douglas Norman and Shield, {C. F.}",
year = "1986",
language = "English (US)",
volume = "18",
pages = "949--953",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - ORTHOCLONE OKT3

T2 - First-line therapy or last option?

AU - Norman, Douglas

AU - Shield, C. F.

PY - 1986

Y1 - 1986

N2 - ORTHOCLONE OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ) a monoclonal anti-T cell antibody with in vitro immunosuppressive properties, is more effective than high-dose steroids for reversing acute renal allograft rejection. It has been used as first-line therapy for first rejection and as the last option for acute rejection, when other therapies have failed. The following report details the experience of two transplant centers on use of ORTHOCLONE OKT3 in renal transplant recipients.

AB - ORTHOCLONE OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ) a monoclonal anti-T cell antibody with in vitro immunosuppressive properties, is more effective than high-dose steroids for reversing acute renal allograft rejection. It has been used as first-line therapy for first rejection and as the last option for acute rejection, when other therapies have failed. The following report details the experience of two transplant centers on use of ORTHOCLONE OKT3 in renal transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=0022452213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022452213&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 949

EP - 953

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -